Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01175356 · ClinicalTrials.gov registry record · Phase 1
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
A Phase 1 study of Ganglioneuroblastoma and Localized Resectable Neuroblastoma, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
- 20
- Study locations
NCT01175356 is a Phase 1 study of Ganglioneuroblastoma and Localized Resectable Neuroblastoma that has completed, run by Children's Oncology Group. The registered enrollment target is 99 participants, below the 1,450-participant average among 8 other Ganglioneuroblastoma trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT01175356, a Phase 1 study of Ganglioneuroblastoma and Localized Resectable Neuroblastoma, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
- 20
- Study locations
Study Summary
This pilot clinical trial studies induction therapy followed by iobenguane I 131 and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and maintenance therapy with isotretinoin. Radioisotope therapy, such as iobenguane I 131, releases radiation that kills tumor cells. Drugs used in chemotherapy, such as carboplatin, etoposide phosphate, busulfan, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant may be able to replace blood-forming cells that are destroyed by iobenguane I 131 and chemotherapy. Giving radioisotope therapy, chemotherapy, and peripheral stem cell transplant may kill more tumor cells.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Cisplatin
- DRUG Busulfan
- PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
- RADIATION 3-Dimensional Conformal Radiation Therapy
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- UCSF Medical Center-Parnassus - San Francisco
- UCSF Medical Center-Mission Bay - San Francisco
Alabama
- Children's Hospital of Alabama - Birmingham
- University of Alabama at Birmingham Cancer Center - Birmingham
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
- Duke University Medical Center - Durham
Texas
- UT Southwestern/Simmons Cancer Center-Dallas - Dallas
- Cook Children's Medical Center - Fort Worth
Arizona
- Phoenix Childrens Hospital - Phoenix
Colorado
- Children's Hospital Colorado - Aurora
Connecticut
- Connecticut Children's Medical Center - Hartford
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2011-12-21 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01175356
The ClinicalTrials.gov registry entry for NCT01175356 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,450-participant average among 8 other Ganglioneuroblastoma trials with a reported enrollment target (93% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Ganglioneuroblastoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01175356 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Alabama, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01175356 about?
NCT01175356 is a clinical study titled "Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin". This pilot clinical trial studies induction therapy followed by iobenguane I 131 and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and maintenance therapy with isotretinoin. Radioisotope therapy, such as iobenguane ...
What is the current status of trial NCT01175356?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2011-12-21. Estimated completion is 2025-12-31.
What conditions does trial NCT01175356 study?
This clinical trial studies the following conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Stage 4 Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma.
What interventions are being tested in trial NCT01175356?
The interventions under investigation include: Cyclophosphamide (DRUG), Cisplatin (DRUG), Busulfan (DRUG), Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE), 3-Dimensional Conformal Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01175356?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01175356 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ganglioneuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RECRUITING · Phase 3
-
Phase II Study of Proton Radiation Therapy for Neuroblastoma
RECRUITING · NA
-
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
ACTIVE NOT RECRUITING
-
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.